Cell-based drug-delivery Platforms

• Ravi Kumar MN . Nano and microparticles as controlled drug delivery devices. J. Pharm. Pharm. Sci.3(2), 234–258 (2000).
   PubMed Web of Science ®Google Scholar
• Yoo JW , IrvineDJ, DischerDE, MitragotriS. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat. Rev. Drug Discov10(7), 521–535 (2011).
   PubMed Web of Science ®Google Scholar
• Rutherford MS , FutchWS, Jr., Schook LB. Acetylated low density lipoprotein and the delivery of immunomodulators to macrophages. Targeted Diagn. Ther.5, 201–223 (1991).
   PubMedGoogle Scholar
• Wu F , WuenschSA, AzadnivM, EbrahimkhaniMR, CrispeIN. Galactosylated LDL nanoparticles: a novel targeting delivery system to deliver antigen to macrophages and enhance antigen specific T cell responses. Mol. Pharm.6(5), 1506–1517 (2009).
   PubMedGoogle Scholar
• Slomkowski S , GoseckiM. Progress in nanoparticulate systems for peptide, proteins and nucleic acid drug delivery. Curr. Pharm. Biotechnol. (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Del Pozo-Rodriguez A , DelgadoD, SolinisMA, GasconAR. Lipid nanoparticles as vehicles for macromolecules: nucleic acids and peptides. Recent Pat. Drug Deliv. Formul.5(3), 214–226 (2011).
   PubMedGoogle Scholar
• Wu TL , ZhouD. Viral delivery for gene therapy against cell movement in cancer. Adv. Drug Deliv. Rev.63(8), 671–677 (2011).
   PubMed Web of Science ®Google Scholar
• Rapti K , ChaanineAH, HajjarRJ. Targeted gene therapy for the treatment of heart failure. Can. J. Cardiol27(3), 265–283 (2011).
   PubMed Web of Science ®Google Scholar
• Millan CG , MarineroML, CastanedaAZ, LanaoJM. Drug, enzyme and peptide delivery using erythrocytes as carriers. J. Control. Release95(1), 27–49 (2004).
   PubMed Web of Science ®Google Scholar
• Hoffman J . On red blood cells, hemolysis and resealed ghosts. in: The Use of Resealed Erythrocytes as Carriers and Bioreactors, Magnani M, Deloach JR (Eds.). Plenum Press, NY, USA, 1–15 (1992).
   Google Scholar
• Hamidi M , TajerzadehH. Carrier erythrocytes: an overview. Drug Deliv.10(1), 9–20 (2003).
   PubMed Web of Science ®Google Scholar
• Jalava K , HenselA, SzostakM, ReschS, LubitzW. Bacterial ghosts as vaccine candidates for veterinary applications. J. Control. Release85(1–3), 17–25 (2002).
   PubMed Web of Science ®Google Scholar
• Huter V , SzostakMP, GampferJet al. Bacterial ghosts as drug carrier and targeting vehicles. J. Control. Release 61(1–2), 51–63 (1999).
   PubMed Web of Science ®Google Scholar
• Lubitz W . Bacterial ghosts as carrier and targeting systems. Expert Opin. Biol. Ther.1(5), 765–771 (2001).
   PubMed Web of Science ®Google Scholar
• Paukner S , StiedlT, KudelaP, BizikJ, Al Laham F, Lubitz W. Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery. Expert Opin. Drug Deliv.3(1), 11–22 (2006).
   PubMedGoogle Scholar
• Altaner C . Prodrug cancer gene therapy. Cancer Lett.270(2), 191–201 (2008).
   PubMed Web of Science ®Google Scholar
• Aboody KS , NajbauerJ, DanksMK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther.15(10), 739–752 (2008).
   PubMed Web of Science ®Google Scholar
• Lanao JM . Biological carrier systems. Advances for drug and gene delivery. G.I.T. Lab. J. Europe5, 36–39 (2006).
   Google Scholar
• Smits EL , AnguilleS, CoolsN, BernemanZN, Van Tendeloo VF. Dendritic cell-based cancer gene therapy. Hum. Gene Ther.20(10), 1106–1118 (2009).
   PubMed Web of Science ®Google Scholar
• Breckpot K , EscorsD. Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification. Endocr. Metab. Immune Disord. Drug Targets9(4), 328–343 (2009).
   PubMedGoogle Scholar
• Tuyaerts S , AertsJL, CorthalsJet al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol. Immunother. 56(10), 1513–1537 (2007).
   PubMed Web of Science ®Google Scholar
• Ma J , GalloJM. Delivery of cytotoxic drugs from carrier cells to tumour cells by apoptosis. Apoptosis3(3), 195–202 (1998).
   PubMed Web of Science ®Google Scholar
• Shao J , DehavenJ, LammDet al. A cell-based drug delivery system for lung targeting: II. Therapeutic activities on B16–F10 melanoma in mouse lungs. Drug Deliv. 8(2), 71–76 (2001).
   PubMed Web of Science ®Google Scholar
• Ong CT , BabalolaCP, NightingaleCH, NicolauDP. Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J. Antimicrob. Chemother.56(3), 498–501 (2005).
   PubMed Web of Science ®Google Scholar
• Manabe T , OkinoH, MaeyamaRet al. Novel strategic therapeutic approaches for prevention of local recurrence of pancreatic cancer after resection: trans-tissue, sustained local drug-delivery systems. J. Control. Release 100(3), 317–330 (2004).
   PubMed Web of Science ®Google Scholar
• Lanao JM , SayaleroML. Cells and cell ghosts as drug carriers. In: Nanoparticulates as Drug Carriers. Torchilin VP (Eds). Imperial College Press, London, UK, 329–348 (2006).
   Google Scholar
• Gutierrez Millan C , Zarzuelo Castaneda A, Sayalero Marinero ML, Lanao JM. Factors associated with the performance of carrier erythrocytes obtained by hypotonic dialysis. Blood Cells Mol. Dis.33(2), 132–140 (2004).
   PubMed Web of Science ®Google Scholar
• Muzykantov VR . Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin. Drug Deliv.7(4), 403–427 (2010).
   PubMed Web of Science ®Google Scholar
• Kwon YM , ChungHS, MoonCet al. L-asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). J. Control. Release139(3), 182–189 (2009).
   PubMed Web of Science ®Google Scholar
• Banz A , CremelM, RembertA, GodfrinY. In situ targeting of dendritic cells by antigen-loaded red blood cells: a novel approach to cancer immunotherapy. Vaccine28(17), 2965–2972 (2010).
   PubMed Web of Science ®Google Scholar
• Bossa F , LatianoA, RossiLet al. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am. J. Gastroenterol. 103(10), 2509–2516 (2008).
   PubMed Web of Science ®Google Scholar
• Harisa GD , IbrahimMF, AlanaziFK. Characterization of human erythrocytes as potential carrier for pravastatin: an in vitro study. Int. J. Med. Sci.8(3), 222–230 (2011).
   PubMed Web of Science ®Google Scholar
• Pitt E , JohnsonCM, LewisDA, JennerDA, OffordRE. Encapsulation of drugs in intact erythrocytes: an intravenous delivery system. Biochem. Pharmacol.32(22), 3359–3368 (1983).
   PubMed Web of Science ®Google Scholar
• Ogiso T , IwakiM, OhtoriA. Encapsulation of dexamethasone in rabbit erythrocytes, the disposition in circulation and anti-inflammatory effect. J. Pharmacobiodyn.8(12), 1032–1040 (1985).
   PubMedGoogle Scholar
• Hamidi M , TajerzadehH, DehpourAR, RouiniMR, Ejtemaee-MehrS. In vitro characterization of human intact erythrocytes loaded by enalaprilat. Drug Deliv.8(4), 223–230 (2001).
   PubMed Web of Science ®Google Scholar
• Eichler HG , GasicS, DaumB, BacherS, StegerG. In vitro drug release from human carrier erythrocytes. Adv. Biosci.67, 11–15 (1987).
   Google Scholar
• Briones E , ColinoCI, LanaoJM. Study of the factors influencing the encapsulation of zidovudine in rat erythrocytes. Int. J. Pharm.401(1–2), 41–46 (2010).
   PubMedGoogle Scholar
• Gutierrez Millan C , BaxBE, CastanedaAZ, MarineroML, LanaoJM. In vitro studies of amikacin-loaded human carrier erythrocytes. Transl. Res.152(2), 59–66 (2008).
   PubMed Web of Science ®Google Scholar
• Bax BE , BainMD, TalbotPJ, Parker-WilliamsEJ, ChalmersRA. Survival of human carrier erythrocytes in vivo. Clin. Sci. (Lond)96(2), 171–178 (1999).
   PubMed Web of Science ®Google Scholar
• Magnani M , RossiL, FraternaleAet al. Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides. Gene Ther. 9(11), 749–751 (2002).
   PubMed Web of Science ®Google Scholar
• Tonetti M , AstroffAB, SatterfieldW, De Flora A, Benatti U, Deloach JR. Pharmacokinetic properties of doxorubicin encapsulated in glutaraldehyde-treated canine erythrocytes. Am. J. Vet. Res.52(10), 1630–1635 (1991).
   PubMed Web of Science ®Google Scholar
• Skorokhod O , KulikovaEV, GalkinaNMet al. Doxorubicin pharmacokinetics in lymphoma patients treated with doxorubicin-loaded eythrocytes. Haematologica 92(4), 570–571 (2007).
   PubMed Web of Science ®Google Scholar
• Yuan SH , GeWH, HuoJ, WangXH. Slow release properties and liver-targeting characteristics of methotrexate erythrocyte carriers. Fund Am. Clin. Pharmacol.23(2), 189–196 (2009).
   PubMed Web of Science ®Google Scholar
• Luo X , XuX, WangXH, ZhuSJ, GeWH. Study of Erythrocyte as carrier to prolong morphine‘s duration of action. J. NanJing Univ. (Nat. Sci.)39, 547–553 (2003).
   Google Scholar
• Wang GP , GuanYS, JinXRet al. Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites. J. Gastroenterol. Hepatol. 25(5), 985–990 (2010).
   PubMed Web of Science ®Google Scholar
• Lizano C , PerezMT, PinillaM. Mouse erythrocytes as carriers for coencapsulated alcohol and aldehyde dehydrogenase obtained by electroporation in vivo survival rate in circulation, organ distribution and ethanol degradation. Life Sci.68(17), 2001–2016 (2001).
   PubMed Web of Science ®Google Scholar
• Alvarez FJ , HerraezA, MurcianoJC, JordanJA, DiezJC, TejedorMC. In vivo survival and organ uptake of loaded carrier rat erythrocytes. J. Biochem.120(2), 286–291 (1996).
   PubMed Web of Science ®Google Scholar
• Gutierrez Millan C , Zarzuelo Castaneda A, Gonzalez Lopez F, Sayalero Marinero ML, Lanao JM. Pharmacokinetics and biodistribution of amikacin encapsulated in carrier erythrocytes. J. Antimicrob. Chemo. Ther.61(2), 375–381 (2008).
   PubMed Web of Science ®Google Scholar
• Briones E , ColinoCI, MillanCG, LanaoJM. Increasing the selectivity of amikacin in rat peritoneal macrophages using carrier erythrocytes. Eur. J. Pharm. Sci.38(4), 320–324 (2009).
   PubMed Web of Science ®Google Scholar
• Rossi L , BrandiG, MalatestaMet al. Effect of listeriolysin O-loaded erythrocytes on Mycobacterium avium replication within macrophages. J. Antimicrob Chemo. Ther. 53(5), 863–866 (2004).
   PubMed Web of Science ®Google Scholar
• Mishra PR , JainNK. Biotinylated methotrexate loaded erythrocytes for enhanced liver uptake. ‘A study on the rat‘. Int. J. Pharm.231(2), 145–153 (2002).
   PubMedGoogle Scholar
• Jordan JA , AlvarezFJ, LoteroLA, HerraezA, DiezJC, TejedorMC. In vitro phagocytosis of carrier mouse red blood cells is increased by Band 3 cross-linking or diamide treatment. Biotechnol. Appl. Biochem.34(3), 143–149 (2001).
   PubMedGoogle Scholar
• Lotero LA , JordanJA, OlmosG, AlvarezFJ, TejedorMC, DiezJC. Differential in vitro and in vivo behavior of mouse ascorbate/Fe3+ and diamide oxidized erythrocytes. Biosci. Rep.21(6), 857–871 (2001).
   PubMed Web of Science ®Google Scholar
• Kim SH , KimEJ, HouJHet al. Opsonized erythrocyte ghosts for liver-targeted delivery of antisense oligodeoxynucleotides. Biomaterials 30(5), 959–967 (2009).
   PubMed Web of Science ®Google Scholar
• Mishra PR , JainNK. Surface modified methotrexate loaded erythrocytes for enhanced macrophage uptake. J. Drug Target8(4), 217–224 (2000).
   PubMed Web of Science ®Google Scholar
• Shavi GV , DoijadRC, DeshpandePBet al. Erythrocytes as carrier for prednisolone: in vitro and in vivo evaluation. Pak. J. Pharm. Sci. 23(2), 194–200 (2010).
   PubMed Web of Science ®Google Scholar
• Kruse CA , FreehaufCL, PatelKR, BaldeschwielerJD. Mouse erythrocyte carriers osmotically loaded with methotrexate. Biotechnol. Appl. Biochem.9(2), 123–140 (1987).
   PubMed Web of Science ®Google Scholar
• Lotero LA , OlmosG, DiezJC. Delivery to macrophages and toxic action of etoposide carried in mouse red blood cells. Biochim. Biophys. Acta.1620(1–3), 160–166 (2003).
   PubMed Web of Science ®Google Scholar
• Zocchi E , TonettiM, PolvaniC, GuidaL, BenattiU, De Flora A. In vivo liver and lung targeting of adriamycin encapsulated in glutaraldehyde-treated murine erythrocytes. Biotechnol. Appl. Biochem.10(6), 555–562 (1988).
   PubMed Web of Science ®Google Scholar
• Briones E , ColinoCI, LanaoJM. Delivery systems to increase the selectivity of antibiotics in phagocytic cells. J. Control. Release125(3), 210–227 (2008).
   PubMed Web of Science ®Google Scholar
• Alanazi F . Pravastatin provides antioxidant activity and protection of erythrocytes loaded Primaquine. Int. J. Med. Sci.7(6), 358–365 (2010).
   PubMed Web of Science ®Google Scholar
• Staedtke V , BrahlerM, MullerAet al. In vitro inhibition of fungal activity by macrophage-mediated sequestration and release of encapsulated amphotericin B nanosupension in red blood cells. Small6(1), 96–103 (2010).
   PubMed Web of Science ®Google Scholar
• Rossi L , SerafiniS, CeneriniLet al. Erythrocyte-mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease. Biotechnol. Appl. Biochem. 33(Pt 2), 85–89 (2001).
   PubMed Web of Science ®Google Scholar
• Castro M , KnafelzD, RossiLet al. Periodic treatment with autologous erythrocytes loaded with dexamethasone 21-phosphate for fistulizing pediatric Crohn‘s disease: case report. J. Pediatr. Gastroenterol. Nutr. 42(3), 313–315 (2006).
   PubMed Web of Science ®Google Scholar
• Rossi L , CastroM, D‘orioFet al. Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. Blood Cells Mol. Dis. 33(1), 57–63 (2004).
   PubMed Web of Science ®Google Scholar
• Lucidi V , TozziAE, BellaS, TurchettaA. A pilot trial on safety and efficacy of erythrocyte-mediated steroid treatment in CF patients. BMC Pediatr.6, 17 (2006).
   PubMedGoogle Scholar
• Annese V , LatianoA, RossiLet al. The polymorphism of multi-drug resistance 1 gene (MDR1) does not influence the pharmacokinetics of dexamethasone loaded into autologous erythrocytes of patients with inflammatory bowel disease. Eur. Rev. Med. Pharmacol. Sci. 10(1), 27–31 (2006).
   PubMedGoogle Scholar
• Hamidi M , AzimiK, Mohammadi-SamaniS. Co-encapsulation of a drug with a protein in erythrocytes for improved drug loading and release: phenytoin and bovine serum albumin (BSA). J. Pharm. Pharm. Sci.14(1), 46–59 (2011).
   PubMed Web of Science ®Google Scholar
• Noël-Hocquet S , JabbouriS, LazarS, MaunierJC, GuillaumetG, RoparsC. Erythrocytes as carriers of new anti-opioid prodrugs: in vitro studies. In: The Use of Erythrocytes as Carriers and Bioreactors. Advances in Experimental Medicine and Biology (vol. 326), Magnani M, De Loach JR (Eds.). Plenum Press, New York, USA, 215–221 (1992).
   Google Scholar
• Zaitsev S , SpitzerD, MurcianoJCet al. Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood 115(25), 5241–5248 (2010).
   PubMed Web of Science ®Google Scholar
• Hamidi M , RafieiP, AzadiA, Mohammadi-SamaniS. Encapsulation of valproate-loaded hydrogel nanoparticles in intact human erythrocytes: a novel nano-cell composite for drug delivery. J. Pharm. Sci.100(5), 1702–1711 (2011).
   PubMed Web of Science ®Google Scholar
• Hudson LD , FiddlerMB, DesnickRJ. Immunologic aspects of enzyme replacement therapy. An evaluation of the immune response to unentrapped, erythrocyte- and liposome-entrapped enzyme in C3H/HeJ Gush mice. Birth Defects Orig. Artic. Ser.16(1), 163–178 (1980).
   PubMedGoogle Scholar
• Kravtzoff R , DesboisI, LamagnereJPet al. Improved pharmacodynamics of L-asparaginase-loaded in human red blood cells. Eur. J. Clin. Pharmacol. 49(6), 465–470 (1996).
   PubMed Web of Science ®Google Scholar
• Domenech C , ThomasX, ChabaudSet al. L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005–2001 randomized trial. Br. J. Haematol.153(1), 58–65 (2011).
   PubMed Web of Science ®Google Scholar
• Thomas X , CannasG, ChelghoumY, GougounonA. Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia. Bull. Cancer97(9), 1105–1117 (2010).
   PubMed Web of Science ®Google Scholar
• Kravtzoff R , RoparsC, LaguerreM, MuhJP, ChassaigneM. Erythrocytes as carriers for L-asparaginase. Methodological and mouse in vivo studies. J. Pharm. Pharmacol.42(7), 473–476 (1990).
   PubMed Web of Science ®Google Scholar
• Naqi A , DeloachJR, AndrewsK, SatterfieldW, KeelingM. Determination of parameters for enzyme therapy using L-asparaginase entrapped in canine erythrocytes. Biotechnol. Appl. Biochem.10(4), 365–372 (1988).
   PubMed Web of Science ®Google Scholar
• Updike SJ . Entrapment of L-asparaginase in red blood cells. A strategy to improve treatment of acute lymphoblastic leukemia. Bibl. Haematol.51, 65–74 (1985).
   Google Scholar
• Rossi L , BianchiM, MagnaniM. Increased glucose metabolism by enzyme-loaded erythrocytes in vitro and in vivo normalization of hyperglycemia in diabetic mice. Biotechnol. Appl. Biochem.15(2), 207–216 (1992).
   PubMed Web of Science ®Google Scholar
• Lizano C , SanzS, LuqueJ, PinillaM. In vitro study of alcohol dehydrogenase and acetaldehyde dehydrogenase encapsulated into human erythrocytes by an electroporation procedure. Biochim. Biophys. Acta.1425(2), 328–336 (1998).
   PubMed Web of Science ®Google Scholar
• Ninfali P , RossiL, BaroncianiL, RoparsC, MagnaniM. Acetaldehyde oxidation by aldehyde dehydrogenase loaded erythrocytes. In: The Use of Erythrocytes as Carriers and Bioreactors. Advances in Experimental Medicine and Biology (vol. 326), Magnani M, De Loach JR (Eds). Plenum Press, NY, USA, 165–173 (1992).
   Google Scholar
• Muthuvel A , RajamaniR, ManikandanS, SheeladeviR. Detoxification of formate by formate dehydrogenase-loaded erythrocytes and carbicarb in folate-deficient methanol-intoxicated rats. Clin. Chim Acta.367(1–2), 162–169 (2006).
   PubMed Web of Science ®Google Scholar
• Magnani M , FaziA, ManganiF, RossiL, ManciniU. Methanol detoxification by enzyme-loaded erythrocytes. Biotechnol. Appl. Biochem.18( Pt 3), 217–226 (1993).
   PubMed Web of Science ®Google Scholar
• Sanz S , LizanoC, LuqueJ, PinillaM. In vitro and in vivo study of glutamate dehydrogenase encapsulated into mouse erythrocytes by a hypotonic dialysis procedure. Life Sci.65(26), 2781–2789 (1999).
   PubMed Web of Science ®Google Scholar
• Cannon EP , LeungP, HawkinsA, PetrikovicsI, DeloachJ, WayJL. Antagonism of cyanide intoxication with murine carrier erythrocytes containing bovine rhodanese and sodium thiosulfate. J. Toxicol. Environ. Health41(3), 267–274 (1994).
   PubMed Web of Science ®Google Scholar
• Petrikovics I , PeiL, McguinnWD, CannonEP, WayJL. Encapsulation of rhodanese and organic thiosulfonates by mouse erythrocytes. Fundam. Appl. Toxicol.23(1), 70–75 (1994).
   PubMedGoogle Scholar
• Magnani M , ManciniU, BianchiM, FaziA. Comparision of uricase-bound and uricase-loaded erythrocytes as bioreactors for uric acid degradation. In: The Use of Erythrocytes as Carriers and Bioreactors. Advances in Experimental Medicine and Biology (vol. 326). Magnani M, De Loach JR (Eds). Plenum Press, NY, USA, 189–194 (1992).
   Google Scholar
• Ito Y , OgisoT, IwakiM, AtagoH. Encapsulation of human urokinase in rabbit erythrocytes and its disposition in the circulation system in rabbits. J. Pharmacobiodyn.10(10), 550–556 (1987).
   PubMedGoogle Scholar
• Garin M , RossiL, LuqueJ, MagnaniM. Lactate catabolism by enzyme-loaded red blood cells. Biotechnol. Appl. Biochem.22(Pt 3), 295–303 (1995).
   PubMed Web of Science ®Google Scholar
• Adriaenssens K , KarcherD, MarescauB, Van Broeckhoven C, Lowenthal A, Terheggen HC. Hyperargininemia: the rat as a model for the human disease and the comparative response to enzyme replacement therapy with free arginase and arginase-loaded erythrocytes in vivo. Int. J. Biochem.16(7), 779–786 (1984).
   PubMedGoogle Scholar
• Pei L , OmburoG, McguinnWDet al. Encapsulation of phosphotriesterase within murine erythrocytes. Toxicol. Appl. Pharmacol. 124(2), 296–301 (1994).
   PubMed Web of Science ®Google Scholar
• Bustos NL , BatlleAM. Enzyme replacement therapy in porphyrias – V. In vivo correction of delta-aminolaevulinate dehydratase defective in erythrocytes in lead intoxicated animals by enzyme-loaded red blood cell ghosts. Drug Des. Deliv.5(2), 125–131 (1989).
   PubMedGoogle Scholar
• Hamarat Baysal S , UslanAH. In vitro study of urease/AlaDH enzyme system encapsulated into human erythrocytes and research into its medical applications. Artif. Cells Blood Substit. Immobil. Biotechnol.30(1), 71–77 (2002).
   PubMedGoogle Scholar
• Bax BE , BainMD, FairbanksLD, SimmondsHA, WebsterAD, ChalmersRA. Carrier erythrocyte entrapped adenosine deaminase therapy in adenosine deaminase deficiency. Adv. Exp Med. Biol486, 47–50 (2000).
   PubMed Web of Science ®Google Scholar
• Flynn G , HackettTJ, MchaleL, MchaleAP. Encapsulation of the thrombolytic enzyme, brinase, in photosensitized erythrocytes: a novel thrombolytic system based on photodynamic activation. J. Photochem. Photobiol. B26(2), 193–196 (1994).
   PubMed Web of Science ®Google Scholar
• Bax BE , BainMD, WardCP, FensomAH, ChalmersRA. The entrapment of mannose-terminated glucocerebrosidase (Alglucerase) in human carrier erythrocytes. Biochem. Soc. Trans.24(3), 441S (1996).
   PubMedGoogle Scholar
• Moran NF , BainMD, MuqitMM, BaxBE. Carrier erythrocyte entrapped thymidine phosphorylase therapy for MNGIE. Neurology71(9), 686–688 (2008).
   PubMed Web of Science ®Google Scholar
• Biagiotti S , RossiL, BianchiMet al. Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs. J. Control. Release 154(3), 306–313 (2011).
   PubMed Web of Science ®Google Scholar
• Rossi L , SerafiniS, AntonelliAet al. Macrophage depletion induced by clodronate-loaded erythrocytes. J. Drug Target 13(2), 99–111 (2005).
   PubMed Web of Science ®Google Scholar
• Lanao JM , BrionesE, ColinoCI. Recent advances in delivery systems for anti-HIV1 therapy. J. Drug Target15(1), 21–36 (2007).
   PubMed Web of Science ®Google Scholar
• Biagiotti S , RossiL, BianchiMet al. Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs. J. Control. Release 154(3), 306–313 (2011).
   PubMed Web of Science ®Google Scholar
• Magnani M , RossiL, BrandiG, SchiavanoGF, MontroniM, PiedimonteG. Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies. Proc. Natl Acad. Sci. U S A89(14), 6477–6481 (1992).
   PubMed Web of Science ®Google Scholar
• Nielsen PE . Antisense peptide nucleic acids. Curr. Opin. Mol. Ther.2(3), 282–287 (2000).
   PubMedGoogle Scholar
• Chiarantini L , CerasiA, FraternaleAet al. Inhibition of macrophage iNOS by selective targeting of antisense PNA. Biochemistry 41(26), 8471–8477 (2002).
   PubMed Web of Science ®Google Scholar
• Fraternale A , PaolettiMF, CasabiancaAet al. Erythrocytes as carriers of antisense PNA addressed against HIV-1 gag-pol transframe domain. J. Drug Target 17(4), 278–285 (2009).
   PubMed Web of Science ®Google Scholar
• Fraternale A , CasabiancaA, TonelliA, ChiarantiniL, BrandiG, MagnaniM. New drug combinations for the treatment of murine AIDS and macrophage protection. Eur. J. Clin. Invest31(3), 248–252 (2001).
   PubMed Web of Science ®Google Scholar
• Fraternale A , CasabiancaA, RossiLet al. Erythrocytes as carriers of reduced glutathione (GSH) in the treatment of retroviral infections. J. Antimicrob Chemother. 52(4), 551–554 (2003).
   PubMed Web of Science ®Google Scholar
• Rossi L , FranchettiP, PierigeFet al. Inhibition of HIV-1 replication in macrophages by a heterodinucleotide of lamivudine and tenofovir. J. Antimicrob Chemo. Ther. 59(4), 666–675 (2007).
   PubMed Web of Science ®Google Scholar
• Cervasi B , PaiardiniM, SerafiniSet al. Administration of fludarabine-loaded autologous red blood cells in simian immunodeficiency virus-infected sooty mangabeys depletes pSTAT-1-expressing macrophages and delays the rebound of viremia after suspension of antiretroviral therapy. J. Virol 80(21), 10335–10345 (2006).
   PubMed Web of Science ®Google Scholar
• Garin MI , LopezRM, LuqueJ. Pharmacokinetic properties and in vivo biological activity of recombinant human erythropoietin encapsulated in red blood cells. Cytokine9(1), 66–71 (1997).
   PubMed Web of Science ®Google Scholar
• Eichler HG , SchneiderW, RabergerG, BacherS, PabingerI. Erythrocytes as carriers for heparin. Preliminary in vitro and animal studies. Res. Exp. Med. (Berl.)186(6), 407–412 (1986).
   PubMedGoogle Scholar
• Sinauridze EI , VuimoTA, KulikovaEV, Shmyrev,II, AtaullakhanovFI. A new drug form of blood coagulation factor IX: red blood cell-entrapped factor IX. Med. Sci. Monit.16(10), PI19–PI26 (2010).
   PubMed Web of Science ®Google Scholar
• Ganguly K , KrasikT, MedinillaSet al. Blood clearance and activity of erythrocyte-coupled fibrinolytics. J. Pharmacol. Exp Ther. 312(3), 1106–1113 (2005).
   PubMed Web of Science ®Google Scholar
• Murciano JC , HigaziAA, CinesDB, MuzykantovVR. Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile. J. Control. Release139(3), 190–196 (2009).
   PubMed Web of Science ®Google Scholar
• Gersh KC , ZaitsevS, MuzykantovV, CinesDB, WeiselJW. The spatial dynamics of fibrin clot dissolution catalyzed by erythrocyte-bound vs. free fibrinolytics. J. Thromb. Haemost.8(5), 1066–1074 (2010).
   PubMed Web of Science ®Google Scholar
• Feder R , NehushtaiR, MorA. Affinity driven molecular transfer from erythrocyte membrane to target cells. Peptides22(10), 1683–1690 (2001).
   PubMed Web of Science ®Google Scholar
• Olmos G , LoteroLA, TejedorMC, DiezJC. Delivery to macrophages of interleukin 3 loaded in mouse erythrocytes. Biosci. Rep.20(5), 399–410 (2000).
   PubMed Web of Science ®Google Scholar
• Polvani C , GaspariniA, BenattiUet al. Murine red blood cells as efficient carriers of three bacterial antigens for the production of specific and neutralizing antibodies. Biotechnol. Appl. Biochem. 14(3), 347–356 (1991).
   PubMed Web of Science ®Google Scholar
• Garin MI , LopezRM, SanzS, PinillaM, LuqueJ. Erythrocytes as carriers for recombinant human erythropoietin. Pharm. Res.13(6), 869–874 (1996).
   PubMed Web of Science ®Google Scholar
• Eichler HG , GasicS, BauerK, KornA, BacherS. In vivo clearance of antibody-sensitized human drug carrier erythrocytes. Clin. Pharmacol. Ther.40(3), 300–303 (1986).
   PubMed Web of Science ®Google Scholar
• Murray AM , PearsonIF, FairbanksLD, ChalmersRA, BainMD, BaxBE. The mouse immune response to carrier erythrocyte entrapped antigens. Vaccine24(35–36), 6129–6139 (2006).
   PubMed Web of Science ®Google Scholar
• Hamidi M , ZareiN, ZarrinAH, Mohammadi-SamaniS. Preparation and in vitro characterization of carrier erythrocytes for vaccine delivery. Int. J. Pharm.338(1–2), 70–78 (2007).
   PubMed Web of Science ®Google Scholar
• Hamidi M , ZareiN, ZarrinA, Mohammadi-SamaniS. Preparation and validation of carrier human erythrocytes loaded by bovine serum albumin as a model antigen/protein. Drug Deliv.14(5), 295–300 (2007).
   PubMed Web of Science ®Google Scholar
• Hamidi M , ZarrinAH, ForoozeshM, ZareiN, Mohammadi-SamaniS. Preparation and in vitro evaluation of carrier erythrocytes for RES-targeted delivery of interferon-alpha 2b. Int. J. Pharm.341(1–2), 125–133 (2007).
   PubMed Web of Science ®Google Scholar
• Byun HM , SuhD, YoonHet al. Erythrocyte ghost-mediated gene delivery for prolonged and blood-targeted expression. Gene Ther. 11(5), 492–496 (2004).
   PubMed Web of Science ®Google Scholar
• Doshi N , ZahrAS, BhaskarS, LahannJ, MitragotriS. Red blood cell-mimicking synthetic biomaterial particles. Proc. Natl Acad. Sci. USA106(51), 21495–21499 (2009).
   PubMed Web of Science ®Google Scholar
• Liu ZC , ChangTM. Long-term effects on the histology and function of livers and spleens in rats after 33% toploading of PEG–PLA-nano artificial red blood cells. Artif Cells Blood Substit Immobil Biotechnol.36(6), 513–524 (2008).
   PubMed Web of Science ®Google Scholar
• Desilets J , LejeuneA, MercerJ, GicquaudC. Nanoerythrosomes, a new derivative of erythrocyte ghost: IV. Fate of reinjected nanoerythrosomes. Anticancer Res.21(3B), 1741–1747 (2001).
   PubMed Web of Science ®Google Scholar
• Lejeune A , PoyetP, GaudreaultRC, GicquaudC. Nanoerythrosomes, a new derivative of erythrocyte ghost: III. Is phagocytosis involved in the mechanism of action? Anticancer Res.17(5A), 3599–3603 (1997).
   PubMed Web of Science ®Google Scholar
• Pouliot R , Saint-LaurentA, ChypreCet al. Spectroscopic characterization of nanoerythrosomes in the absence and presence of conjugated polyethyleneglycols: an FTIR and (31)P-NMR study. Biochim. Biophys. Acta. 1564(2), 317–324 (2002).
   PubMed Web of Science ®Google Scholar
• Witte A , WannerG, SulznerM, LubitzW. Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli. Arch Microbiol157(4), 381–388 (1992).
   PubMed Web of Science ®Google Scholar
• Marchart J , DropmannG, LechleitnerSet al. Pasteurella multocida- and Pasteurella haemolytica-ghosts: new vaccine candidates. Vaccine 21(25–26), 3988–3997 (2003).
   PubMed Web of Science ®Google Scholar
• Witte A , WannerG, BlasiU, HalfmannG, SzostakM, LubitzW. Endogenous transmembrane tunnel formation mediated by phi X174 lysis protein E. J. Bacteriol.172(7), 4109–4114 (1990).
   PubMed Web of Science ®Google Scholar
• Paukner S , KohlG, LubitzW. Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells. J. Control. Release94(1), 63–74 (2004).
   PubMed Web of Science ®Google Scholar
• Szostak MP , HenselA, EkoFOet al. Bacterial ghosts: non-living candidate vaccines. J. Biotechnol. 44(1–3), 161–170 (1996).
   PubMed Web of Science ®Google Scholar
• Langemann T , KollerVJ, MuhammadA, KudelaP, MayrUB, LubitzW. The bacterial ghost platform system: Production and applications. Bioeng. Bugs1(5), 326–336 (2010).
   PubMedGoogle Scholar
• Tabrizi CA , WalcherP, MayrUBet al. Bacterial ghosts – biological particles as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol. 15(6), 530–537 (2004).
   PubMed Web of Science ®Google Scholar
• Mayr UB , WalcherP, AzimpourC, RiedmannE, HallerC, LubitzW. Bacterial ghosts as antigen delivery vehicles. Adv. Drug Deliv. Rev.57(9), 1381–1391 (2005).
   PubMed Web of Science ®Google Scholar
• Witte A , LubitzW. Biochemical characterization of phi X174-protein-E-mediated lysis of Escherichia coli. Eur. J. Biochem.180(2), 393–398 (1989).
   PubMedGoogle Scholar
• Kwon SR , KangYJ, LeeDJet al. Generation of Vibrio anguillarum ghost by coexpression of PhiX 174 lysis E gene and Staphylococcal nuclease A gene. Mol. Biotechnol. 42(2), 154–159 (2009).
   PubMed Web of Science ®Google Scholar
• Jalava K , EkoFO, RiedmannE, LubitzW. Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert Rev. Vaccines2(1), 45–51 (2003).
   PubMedGoogle Scholar
• Yu SY , PengW, SiWet al. Enhancement of bacteriolysis of Shuffled phage PhiX174 gene E. Virol J. 8, 206 (2011).
   PubMed Web of Science ®Google Scholar
• Resch S , GruberK, WannerG, SlaterS, DennisD, LubitzW. Aqueous release and purification of poly(beta-hydroxybutyrate) from Escherichia coli. J. Biotechnol.65(2–3), 173–182 (1998).
   PubMed Web of Science ®Google Scholar
• Paukner S , KohlG, JalavaK, LubitzW. Sealed bacterial ghosts – novel targeting vehicles for advanced drug delivery of water-soluble substances. J. Drug Target11(3), 151–161 (2003).
   PubMed Web of Science ®Google Scholar
• Lubitz W , WitteA, EkoFOet al. Extended recombinant bacterial ghost system. J. Biotechnol. 73(2–3), 261–273 (1999).
   PubMed Web of Science ®Google Scholar
• Paukner S , KudelaP, KohlG, SchlappT, FriedrichsS, LubitzW. DNA-loaded bacterial ghosts efficiently mediate reporter gene transfer and expression in macrophages. Mol. Ther.11(2), 215–223 (2005).
   PubMed Web of Science ®Google Scholar
• Haidinger W , SzostakMP, JechlingerW, LubitzW. Online monitoring of Escherichia coli ghost production. Appl. Environ. Microbiol.69(1), 468–474 (2003).
   PubMed Web of Science ®Google Scholar
• Haidinger W , SzostakMP, BeiskerW, LubitzW. Green fluorescent protein (GFP)-dependent separation of bacterial ghosts from intact cells by FACS. Cytometry44(2), 106–112 (2001).
   PubMedGoogle Scholar
• Kudela P , KollerVJ, LubitzW. Bacterial ghosts (BGs) – advanced antigen and drug delivery system. Vaccine28(36), 5760–5767 (2010).
   PubMed Web of Science ®Google Scholar
• Haslberger AG , KohlG, FelnerovaD, MayrUB, Furst-LadaniS, LubitzW. Activation, stimulation and uptake of bacterial ghosts in antigen presenting cells. J. Biotechnol.83(1–2), 57–66 (2000).
   PubMed Web of Science ®Google Scholar
• Mader HJ , SzostakMP, HenselA, LubitzW, HaslbergerAG. Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines. Vaccine15(2), 195–202 (1997).
   PubMed Web of Science ®Google Scholar
• Eko FO , WitteA, HuterVet al. New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Vaccine 17(13–14), 1643–1649 (1999).
   PubMed Web of Science ®Google Scholar
• Mayr UB , HallerC, HaidingerWet al. Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge. Infect. Immun. 73(8), 4810–4817 (2005).
   PubMed Web of Science ®Google Scholar
• Riedmann EM , KydJM, CrippsAW, LubitzW. Bacterial ghosts as adjuvant particles. Expert Rev. Vaccines6(2), 241–253 (2007).
   PubMed Web of Science ®Google Scholar
• Walcher P , MayrUB, Azimpour-TabriziCet al. Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors. Expert Rev. Vaccines 3(6), 681–691 (2004).
   PubMedGoogle Scholar
• Donnelly JJ , UlmerJB, ShiverJW, LiuMA. DNA vaccines. Annu. Rev. Immunol15, 617–648 (1997).
   PubMed Web of Science ®Google Scholar
• Felnerova D , KudelaP, BizikJet al. T cell-specific immune response induced by bacterial ghosts. Med. Sci. Monit. 10(10), BR362–370 (2004).
   PubMed Web of Science ®Google Scholar
• Kudela P , PauknerS, MayrUBet al. Effective gene transfer to melanoma cells using bacterial ghosts. Cancer Lett. 262(1), 54–63 (2008).
   PubMed Web of Science ®Google Scholar
• Krishnan L , DicaireCJ, PatelGB, SprottGD. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum. Infect. Immun.68(1), 54–63 (2000).
   PubMed Web of Science ®Google Scholar
• Sprott GD , PatelGB, KrishnanL. Archaeobacterial ether lipid liposomes as vaccine adjuvants. Methods Enzymol.373, 155–172 (2003).
   PubMed Web of Science ®Google Scholar
• Scholl I , Boltz-NitulescuG, Jensen-JarolimE. Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy. J. Control. Release104(1), 1–27 (2005).
   PubMed Web of Science ®Google Scholar
• Zhao Y , WangS. Human NT2 neural precursor-derived tumor-infiltrating cells as delivery vehicles for treatment of glioblastoma. Hum. Gene Ther.21(6), 683–694 (2010).
   PubMed Web of Science ®Google Scholar
• Chiu AY , RaoMS. Cell-based therapy for neural disorders – anticipating challenges. Neurotherapeutics8(4), 744–752 (2011).
   PubMed Web of Science ®Google Scholar
• Dhara SK , MajumderA, DodlaMC, SticeSL. Nonviral gene delivery in neural progenitors derived from human pluripotent stem cells. Methods Mol. Biol767, 343–354 (2011).
   PubMedGoogle Scholar
• Porada CD , ZanjaniED, Almeida-PoradG. Adult mesenchymal stem cells: a pluripotent population with multiple applications. Curr. Stem Cell Res. Ther.1(3), 365–369 (2006).
   PubMedGoogle Scholar
• Studeny M , MariniFC, DembinskiJLet al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl Cancer Inst 96(21), 1593–1603 (2004).
   PubMed Web of Science ®Google Scholar
• Loebinger MR , SageEK, JanesSM. Mesenchymal stem cells as vectors for lung disease. Proc Am. Thorac. Soc.5(6), 711–716 (2008).
   PubMedGoogle Scholar
• Min CK , KimBG, ParkG, ChoB, OhIH. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. Bone Marrow Transplant39(10), 637–645 (2007).
   PubMed Web of Science ®Google Scholar
• Yang H , JooKI, ZieglerL, WangP. Cell type-specific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule. Pharm. Res.26(6), 1432–1445 (2009).
   PubMed Web of Science ®Google Scholar
• Ehtesham M , KabosP, KabosovaA, NeumanT, BlackKL, YuJS. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res.62(20), 5657–5663 (2002).
   PubMed Web of Science ®Google Scholar
• Park KI , HimesBT, StiegPE, TesslerA, FischerI, SnyderEY. Neural stem cells may be uniquely suited for combined gene therapy and cell replacement: evidence from engraftment of neurotrophin-3-expressing stem cells in hypoxic-ischemic brain injury. Exp. Neurol.199(1), 179–190 (2006).
   PubMed Web of Science ®Google Scholar
• Elzaouk L , MoellingK, PavlovicJ. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp. Dermatol.15(11), 865–874 (2006).
   PubMed Web of Science ®Google Scholar
• Yang SY , LiuH, ZhangJN. Gene therapy of rat malignant gliomas using neural stem cells expressing IL-12. DNA Cell Biol.23(6), 381–389 (2004).
   PubMed Web of Science ®Google Scholar
• Frank RT , EdmistonM, KendallSEet al. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. PLoS One 4(12), e8314 (2009).
   PubMed Web of Science ®Google Scholar
• Yip S , SabetrasekhR, SidmanRL, SnyderEY. Neural stem cells as novel cancer therapeutic vehicles. Eur. J. Cancer42(9), 1298–1308 (2006).
   PubMed Web of Science ®Google Scholar
• Ahmed AU , LesniakMS. Glioblastoma multiforme: can neural stem cells deliver the therapeutic payload and fulfill the clinical promise? Expert Rev. Neurother.11(6), 775–777 (2011).
   PubMed Web of Science ®Google Scholar
• Aboody KS , NajbauerJ, SchmidtNOet al. Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro Oncol 8(2), 119–126 (2006).
   PubMed Web of Science ®Google Scholar
• Dieterlen MT , WegnerF, SchwarzSCet al. Non-viral gene transfer by nucleofection allows stable gene expression in human neural progenitor cells. J. Neurosci. Methods 178(1), 15–23 (2009).
   PubMed Web of Science ®Google Scholar
• Scaife MD , NeschadimA, FowlerDH, MedinJA. Novel application of lentiviral vectors towards treatment of graft-versus-host disease. Expert Opin. Biol. Ther.9(6), 749–761 (2009).
   PubMed Web of Science ®Google Scholar
• Brenner S , MalechHL. Current developments in the design of onco-retrovirus and lentivirus vector systems for hematopoietic cell gene therapy. Biochim. Biophys. Acta.1640(1), 1–24 (2003).
   PubMed Web of Science ®Google Scholar
• Trobridge GD . Foamy virus vectors for gene transfer. Expert Opin. Biol. Ther.9(11), 1427–1436 (2009).
   PubMed Web of Science ®Google Scholar
• Su L , LeeR, BonyhadiMet al. Hematopoietic stem cell-based gene therapy for acquired immunodeficiency syndrome: efficient transduction and expression of RevM10 in myeloid cells in vivo and in vitro. Blood 89(7), 2283–2290 (1997).
   PubMed Web of Science ®Google Scholar
• Trobridge GD , WuRA, BeardBCet al. Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One 4(11), e7693 (2009).
   PubMed Web of Science ®Google Scholar
• Huber A , PadrunV, DeglonN, AebischerP, MohlerH, BoisonD. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc. Natl Acad. Sci. USA98(13), 7611–7616 (2001).
   PubMed Web of Science ®Google Scholar
• Boison D , HuberA, PadrunV, DeglonN, AebischerP, MohlerH. Seizure suppression by adenosine-releasing cells is independent of seizure frequency. Epilepsia43(8), 788–796 (2002).
   PubMed Web of Science ®Google Scholar
• Boison D . Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies. Epilepsy Res.85(2–3), 131–141 (2009).
   PubMed Web of Science ®Google Scholar
• Sunkomat JN , GaballaMA. Stem cell therapy in ischemic heart disease. Cardiovasc. Drug Rev.21(4), 327–342 (2003).
   PubMedGoogle Scholar
• Makar TK , TrislerD, BeverCTet al. Stem cell based delivery of IFN-beta reduces relapses in experimental autoimmune encephalomyelitis. J. Neuroimmunol 196(1–2), 67–81 (2008).
   PubMed Web of Science ®Google Scholar
• Peng LH , TsangSY, TabataY, GaoJQ. Genetically-manipulated adult stem cells as therapeutic agents and gene delivery vehicle for wound repair and regeneration. J. Control. Release doi:10.1016/j.jconrel.2011.08.027 (2011) (Epub ahead of print).
   Google Scholar
• Facca S , FerrandA, Mendoza-PalomaresCet al. Bone formation induced by growth factors embedded into the nanostructured particles. J. Biomed. Nanotechnol 7(3), 482–485 (2011).
   PubMed Web of Science ®Google Scholar
• Draube A , Klein-GonzalezN, MattheusSet al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One 6(4), e18801 (2011).
   PubMed Web of Science ®Google Scholar
• Tkachenko N , WojasK, TabarkiewiczJ, RolinskiJ. Generation of dendritic cells from human peripheral blood monocytes – comparison of different culture media. Folia. Histochem. Cytobiol43(1), 25–30 (2005).
   PubMed Web of Science ®Google Scholar
• Toscano MG , DelgadoM, KongW, MartinF, SkaricaM, GaneaD. Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. Mol. Ther.18(5), 1035–1045 (2010).
   PubMed Web of Science ®Google Scholar
• Birkholz K , SchwenkertM, KellnerCet al. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood 116(13), 2277–2285 (2010).
   PubMed Web of Science ®Google Scholar
• Breckpot K , HeirmanC, NeynsB, ThielemansK. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. J. Gene Med.6(11), 1175–1188 (2004).
   PubMed Web of Science ®Google Scholar
• Van Nuffel AM , CorthalsJ, NeynsB, HeirmanC, ThielemansK, BonehillA. Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation. Methods Mol. Biol.629, 405–452 (2010).
   PubMedGoogle Scholar
• Arce F , KochanG, BreckpotK, StephensonH, EscorsD. Selective activation of intracellular signalling pathways in dendritic cells for cancer immunotherapy. Anticancer Agents Med. Chem. (2011) (Epub ahead of print).
   Google Scholar
• Puig-Kroger A , RellosoM, Fernandez-CapetilloOet al. Extracellular signal-regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells. Blood 98(7), 2175–2182 (2001).
   PubMed Web of Science ®Google Scholar
• Escors D , LopesL, LinRet al. Targeting dendritic cell signaling to regulate the response to immunization. Blood 111(6), 3050–3061 (2008).
   PubMed Web of Science ®Google Scholar
• Arce F , BreckpotK, StephensonHet al. Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum. 63(1), 84–95 (2011).
   PubMedGoogle Scholar
• Song XT , Evel-KablerK, ShenL, RollinsL, HuangXF, ChenSY. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat. Med.14(3), 258–265 (2008).
   PubMed Web of Science ®Google Scholar
• Breckpot K , Aerts-ToegaertC, HeirmanCet al. Attenuated expression of A20 markedly increases the efficacy of double-stranded RNA-activated dendritic cells as an anti-cancer vaccine. J. Immunol 182(2), 860–870 (2009).
   PubMed Web of Science ®Google Scholar
• Kool M , Van Loo G, Waelput W et al. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity35(1), 82–96 (2011).
   PubMed Web of Science ®Google Scholar
• Matmati M , JacquesP, MaelfaitJet al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat. Genet. 43(9), 908–912 (2011).
   PubMed Web of Science ®Google Scholar
• Akazawa T , ShingaiM, SasaiMet al. Tumor immunotherapy using bone marrow-derived dendritic cells overexpressing Toll-like receptor adaptors. FEBS Lett. 581(18), 3334–3340 (2007).
   PubMed Web of Science ®Google Scholar
• Lambrecht BN . Dendritic cells and the regulation of the allergic immune response. Allergy60(3), 271–282 (2005).
   PubMed Web of Science ®Google Scholar
• Stoop JN , RobinsonJH, HilkensCM. Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models? Ann. Rheum. Dis.70(9), 1526–1533 (2011).
   PubMed Web of Science ®Google Scholar
• Zhao Y , ZhangA, DuH, GuoS, NingB, YangS. Tolerogenic dendritic cells and rheumatoid arthritis: current status and perspectives. Rheumatol. Int. (2011) (Epub ahead of print).
   Google Scholar
• Patham B , SimmonsGL, SubramanyaS. Advances in dendritic cell-based vaccines for HIV. Curr. Med. Chem.18(26), 3987–3994 (2011).
   PubMed Web of Science ®Google Scholar

Website

• Menon LG, Shi VJ, Carroll RS. Mesenchymal stromal cells as a drug delivery system. In: StemBook. Silberstein L (Ed.). The Stem Cell Research Community. Harvard Stem Cell Institute, Harvard University, USA. StemBook, 10.3824/stembook.1.35.1 (15 Jan 2009). www.stembook.org/node/534
   Google Scholar